Kanbayashi Yuko, Ishikawa Takeshi, Taguchi Tetsuya, Takayama Koichi
Department of Outpatient Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan;
Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan.
In Vivo. 2025 Mar-Apr;39(2):902-908. doi: 10.21873/invivo.13894.
BACKGROUND/AIM: This retrospective study aimed to identify factors contributing to blood glucose elevation associated with olanzapine use and to develop new strategies involving olanzapine aimed at enhancing quality of life in patients undergoing chemotherapy.
This study enrolled 220 cancer patients undergoing chemotherapy between January 2017 and May 2022 at our outpatient chemotherapy center. Variables related to the development of olanzapine-associated blood glucose elevation were extracted from medical records for use in regression analysis. We assessed the severity of blood glucose elevation based on the most recent blood glucose level measured after the final administration of olanzapine. Random blood glucose levels were scored as follows: 0, <140 mg/dl; 1, 140-200 mg/dl; or 2, >200 mg/dl. Multivariate ordered logistic regression analysis was performed to identify potential factors in the development of blood glucose elevations associated with olanzapine.
Factors correlated with olanzapine-associated blood glucose elevation included pre-chemotherapy random blood glucose level (=0.002), gastric cancer (=0.003), and the use of calcium channel blockers (=0.048). Although concomitant use of renin-angiotensin system inhibitors showed a tendency toward an association with elevated blood glucose levels, this finding was not statistically significant.
Identifying potential factors contributing to olanzapine-associated blood glucose elevation may assist in developing strategies to improve quality of life for patients undergoing chemotherapy.
背景/目的：本回顾性研究旨在确定与使用奥氮平相关的血糖升高的影响因素，并制定涉及奥氮平的新策略，以提高化疗患者的生活质量。
本研究纳入了2017年1月至2022年5月在我院门诊化疗中心接受化疗的220例癌症患者。从病历中提取与奥氮平相关的血糖升高发展相关的变量，用于回归分析。我们根据奥氮平最后一次给药后测量的最新血糖水平评估血糖升高的严重程度。随机血糖水平评分如下：0，<140mg/dl；1，140 - 200mg/dl；或2，>200mg/dl。进行多变量有序逻辑回归分析，以确定与奥氮平相关的血糖升高发展中的潜在因素。
与奥氮平相关的血糖升高相关的因素包括化疗前随机血糖水平（=0.002）、胃癌（=0.003）和使用钙通道阻滞剂（=0.048）。虽然同时使用肾素 - 血管紧张素系统抑制剂显示出与血糖水平升高相关的趋势，但这一发现无统计学意义。
确定与奥氮平相关的血糖升高的潜在因素可能有助于制定提高化疗患者生活质量的策略。
